QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 caredx-to-feature-new-ivd-products-and-ivdr-certification-for-alloseq-tx-and-qtype-at-ashi-2025-annual-meeting

Furthers Global Leadership in Donor Organ and Transplant Recipient HLA TypingCareDx, Inc. (NASDAQ:CDNA) – The Transplant Compan...

 btig-reiterates-buy-on-caredx-maintains-22-price-target

BTIG analyst Mark Massaro reiterates CareDx (NASDAQ:CDNA) with a Buy and maintains $22 price target.

 btig-reiterates-buy-on-caredx-maintains-22-price-target

BTIG analyst Mark Massaro reiterates CareDx (NASDAQ:CDNA) with a Buy and maintains $22 price target.

 caredx-urges-noridian-to-preserve-coverage-for-combination-and-personalized-molecular-testing-opposes-surveillance-limits-and-bundled-payments-in-draft-lcd-dl40060

CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, developme...

 caredx-battles-reimbursement-uncertainty-as-market-overlooks-long-term-potential

CareDx, Inc. faces uncertainty with proposed reimbursement changes, but has long-term potential in the $8 billion transplant so...

 william-blair-initiates-coverage-on-caredx-with-market-perform-rating

William Blair analyst Andrew Brackmann initiates coverage on CareDx (NASDAQ:CDNA) with a Market Perform rating.

 wells-fargo-maintains-equal-weight-on-caredx-lowers-price-target-to-14

Wells Fargo analyst Brandon Couillard maintains CareDx (NASDAQ:CDNA) with a Equal-Weight and lowers the price target from $1...

 caredx-names-nathan-smith-as-cfo
CareDx Names Nathan Smith As CFO
08/06/2025 21:10:25

 caredx-narrows-fy2025-sales-guidance-from-365000m-375000m-to-367000m-373000m-vs-370794m-est

CareDx (NASDAQ:CDNA) narrows FY2025 sales outlook from $365.000 million-$375.000 million to $367.000 million-$373.000 million v...

 caredx-q2-adj-eps-010-misses-012-estimate-sales-86679m-miss-90563m-estimate

CareDx (NASDAQ:CDNA) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.12 by 18....

 caredx-publishes-koar-study-in-american-journal-of-transplantation-showcasing-allosure-dd-cfdna-for-enhanced-kidney-rejection-detection-and-biopsy-guidance

KOAR, the Largest Prospective Study of Its Kind, Demonstrates Clinical Utility of AlloSure® in Kidney Transplant SurveillanceAl...

Core News & Articles

https://www.hhs.gov/press-room/hrsa-to-reform-organ-transplant-system.html#:~:text=It%20found%3A,serious%20ethical%20and%20lega...

 craig-hallum-maintains-buy-on-caredx-lowers-price-target-to-26

Craig-Hallum analyst Connor Chamberlain maintains CareDx (NASDAQ:CDNA) with a Buy and lowers the price target from $40 to $26.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION